#1CYTEK TRANSCEND THE CONVENTIONAL Advancing the Next Generation of Cell Analysis July 2021#2Disclaimer Cytek Biosciences, Inc. (the "Cytek," "we," "us," or "our") has filed a registration statement on Form S-1 (File No. 333-257663) including a preliminary prospectus with the Securities and Exchange Commission (the "SEC") in connection with the proposed offering to which this presentation relates. Such registration statement has not yet become effective as of the time of this presentation. Before you invest, you should read the prospectus and the other documents Cytek files with the SEC for more complete information about Cytek and the proposed offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Cytek, any underwriter or any dealer participating in the offering can arrange to send you the prospectus if you request a copy by calling Morgan Stanley & Co. LLC at 866-718-1649 or emailing at [email protected]; Goldman Sachs & Co. LLC at 866-471-2526 or emailing at [email protected]; Piper Sandler & Co. at 800-747-3924 or emailing at [email protected]; or Cowen and Company, LLC at 833-297-2926 or emailing at [email protected]. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. By accepting this information, each recipient agrees that (i) no portion of this presentation may be reproduced or distributed in any format without Cytek's prior express written consent, (ii) it will not copy, reproduce or distribute this presentation, in whole or in part, to any person or party, and (ii) it will use this presentation for the sole purpose of evaluating Cytek. This presentation does not purport to contain all of the information that may be required to evaluate Cytek. This presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. CYTEK MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION CONTAINED HEREIN. CYTEK EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY THAT MAY BE BASED ON ANY INFORMATION SET FORTH IN THIS PRESENTATION, ERRORS THEREIN OR OMISSIONS THEREFROM. YOU SHALL MAKE AN ASSESSMENT OF CYTEK AND ITS SECURITIES INDEPENDENTLY AND WITHOUT RELIANCE EXCLUSIVELY UPON THIS PRESENTATION. This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentations presentation, including, without limitation, statements regarding the cell analysis market and our revenue growth and other GAAP and non GAAP financial metrics, our future results of operations and financial position, our business strategy, prospective products, total addressable market, customer mix, collaborations, plans and objectives of management for future operations, and future results of current and anticipated products are forward looking statements. The words "may," "will, "expect," "anticipate," "aim," "estimate." "intend," "plan," "believe," "is/are likely to." "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this presentation are only predictions and represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. The forward-looking statements are subject to a number of risks, uncertainties and assumptions. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We operate in a very competitive and rapidly changing environment. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements contained in this presentation. There can be no assurance that the opportunity will meet your investment objectives or that you will receive a return of all or part of such investment. Investment results may vary significantly over any given time period. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. We recommend that investors independently evaluate specific investments and strategies. This presentation contains Adjusted EBITDA, a financial measure that is not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of Adjusted EBITDA to the most comparable GAAP measure are included at the end of this slide presentation. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. Cytek is a trademark that we own. Other trademarks appearing in this presentation are the property of their respective holders. This presentation contains information that is highly confidential and/or highly privileged. The information is intended only for the use of individuals or entities to which it is addressed. By agreeing to attend this meeting, you agree to keep all such information and the fact that this meeting has taken place confidential. If you are not the intended recipient, you are hereby notified that any reliance, disclosure, copying, distribution, or taking of any action on the contents of this material is strictly prohibited. CYTEK 2#3Offering Summary Issuer: Ticker (Exchange): Total Shares Offered: Over-Allotment Option: Common Stock to be Outstanding Immediately After This Offering: Indicative Price Range: Estimated Gross Proceeds (at the Midpoint of the Filing Range): Selling Shareholders: Use of Proceeds: Bookrunners: Lock-up Provision: Expected Pricing: Cytek Biosciences, Inc. CTKB (Nasdaq Global Select Market) 14.6MM (81% Primary, 19% Secondary) 15% (100% Primary) 130.8MM excluding the Over-Allotment Option $16.00-$18.00 per share $200MM Primary excluding the Over-Allotment Option $48MM Secondary Jiang Gift Trust for Carrie, Next Generation DNA Fund Continue funding commercial expansion Manufacturing activities Marketing initiatives Research and development Working capital and other general corporate purposes Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Piper Sandler & Co., Cowen and Company, LLC 180 days for directors, executive officers and holders of substantially all outstanding securities July 22, 2021 - H CYTEK | الیا 3#41. 2 3. Cytek is Becoming the Premier Cell Analysis Company Novel, patented FSP platform utilizes the full spectrum of fluorescent signatures to deliver high-resolution, high-content and high-sensitivity cell analysis ***** Cli 111FE K 8 88 Highly intuitive, integrated workflow solutions driving strong adoption with over 750 instruments placed since commercial launch in 2017 Validated platform with over 210 peer-reviewed publications, which continues to accelerate alongside growing applications Delivering rare combination of high revenue growth (60% YoY¹) with profitability (16% Adjusted EBITDA margins2,3) Potential utility across a myriad of research and clinical applications could allow Cytek to access the broader $23Bn cell analysis market4 Comprehensive suite of solutions expands customer base and diversification, and provides recurring revenue opportunity Revenue growth between FY2019-FY2020 We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adj. EBITDA Margin is on a percentage of revenue basis Reconciliation of Non-GAAP figures are in the appendix 2024 market pmiection estimate s CYTEK#5Cytek's Leadership Team Wenbin Jiang, Ph.D. Chief Executive Officer Cosemi /LUMENTUM Valerie Barnett General Counsel Dermira FLUIDIGM WILSON SONSINI Ray Lannigan VP, Global Sales & Service BD Patrik Jeanmonod Chief Financial Officer CORE COVANCE Mark Edinger VP, Scientific Affairs Ming Yan, Ph.D. Chief Technology Officer BD Ne Photonics BD Q³Solutions Ken Riley General Manager BD INTUITIVE Allen Poirson, Ph.D. SVP, Marketing and Corporate Development SONY Accmagetwo AR Biotechnology Maria Jaimes, M.D. VP, Applications BD Melik Ulusu VP, Operations & Integrated Supply Chain BD I PerkinElmer CYTEK 5#61. 2 Investing to Capture the Cell Analysis Opportunity Broad Customer Base and Global Presence Validated Technology Platform 750+ Units Placed 210+ Publications 620+ Customers 25+ Countries Strong Financial Profile $93M 2020 Revenue $15M 2020 Adj. EBITDA 1,2 We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses Reconciliation of Non-GAAP figures are in the appendix Aurora Northern Lights Reagents Cell Sorter S CYTEK 2017 2018 2020 2021 6#7To better understand our immune system, with its large and complex network of different cells and their sub-populations, there has been a growing need for higher complexity cell analysis experiments and assays to analyze MORE cell populations together in a single tube of sample MORE fluorescent tagged biomarkers provided by reagent vendors to identify cell populations MORE lasers and detectors provided by instrument manufacturers to measure these fluorescent biomarkers CYTEK | 7#8We Provide an End-to-End Platform of FSP Solutions Instruments Aurora 488 Application & Service Northern Lights Cell Sorter Reagents & Kits FULL SPECTRUM S-LASER CYTOMETRY AT A GLANCE Com Software CYTEK CYTEK CYTEK 8#9Strategy to Drive Innovation in the Cell Analysis Market Software Instruments لك انا Reagents KII 5 Services Becoming a Comprehensive Solutions Provider and Driving Innovation in Cell Analysis Continue facilitating technical innovation in cell analysis Broad application development across life sciences, and healthcare more broadly: 1 1 Discovery, translational and clinical research Clinical diagnostics CYTEK 9#10Our FSP Platform Allows Us to Address the Broader Cell Analysis Market Agilent BIO-RAD Technologies FLUIDIGM SONY BECKMAN $3.0B Cell ID COULTER Milteny! Biotec $8B Initial TAM (Cell Analysis Market in 2019 Addressable by Flow Cytometry) BD Thermo Fisher SCIENTIFIC Marine Biology $1.9B Cell Proliferation $1.6B Cell Counting & QC $1.0B Single Cell Analysis $2.4B Cell Viability $8B Additional TAM (Cell Analysis Market in 2019 Not Currently Addressable by Flow Cytometry) $23B Long-Term TAM (Total Cell Analysis Market in 2024) Water Supply Contamination $2.4B Cell Signaling ES $1.3B Cell Interaction Alternative Biofuels $1.3B Target ID CYTEK $1.1B Cell Structure 10#11Advancing Cell Analysis with Our Unique FSP Technology Cytek's FSP Technology E Conventional ignored Conoestet ENTIRE emission spectrum is captured across the different module & stitched together to create a spectral signature that combines emission information of fluorochrome excited by all onboard lasers CDB APC T APC Aurora Full Spectrum Alexa Fluor 647 NK cells CD56 Alexa 647 Unmixing CDS PITC NKT calls CD56 Alexa 647 Our FSP platform was purpose- built to advance the next generation of cell analysis by delivering deep insights, high throughputs and ease of use FSP technology enables high sensitivity and high throughput without compromising data quality Allows use of many dyes simultaneously with optimal resolution, which is not possible with conventional cytometers FSP is able to extract autofluorescence to enhance resolution CYTEK 11#12C Our FSP Technology is Powered by Innovative Designs A The fluorescence spectrum from each laser source is collected from multiple laser excitation www CYTEK VIRONA Maximize Resolution & Accuracy A www FOVE Optimized Signal-to-Noise Ratio B V HALLI SPESTRIL DISPLM 562 High Resolution D . PMT APD photodiode 400 600 800 wavelength (m Valuable Insights 1000 1290 B The fluorescence from each laser source is collected by each corresponding detector array module C Use of APD detectors maximizes sensitivity and enables broad wavelength responses D The combination of our patented optical design with APD detectors yields high- resolution data at an optimized signal-to-noise ratio CYTEK 12#13Benefits of Our FSP Platform xx Ultra-sensitive Resolves the most challenging cell populations Deep, high-integrity content Highly complex assays through access to 40 different colors in a single tube Flexible and compatible Single configuration across a wide range of reagents and applications Efficient and compact Saves time and money while maintaining industry-leading performance Integrated and intuitive Fully integrated workflows with end-to-end solutions CYTEK 13#14Cytek's Core Instruments: Aurora and Northern Lights >40 Colors from 3-5 Lasers CYTEK AURORA Aurora Biopharma, CROS, Large Academic Labs High-Throughput High-End Market xx Flexible & Intuitive >24 Colors from 1-3 Lasers Northern Lights CYTEK jike Ultra-Sensitive Individual Researchers & Clinical Labs Entry-Level Market Valuable Insights 14#15Newly Launched: Aurora Cell Sorter Overview Aurora Cell Sorter Shipped June 2021 First highly flexible, intuitive and ultra-sensitive cell sorter that leverages the detection and sensitivity capabilities of our FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers Unique . ▪ Able to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers Accommodates the same number of parameters with the same sensitivity as the Aurora system . Ability to easily transfer panels from Aurora, as well as other or conventional instruments, to sorter ■ Easy integration for downstream analysis (e.g., genomics and proteomics) Differentiated Can analyze and sort using higher complexity panels, in addition to ability to isolate living cell populations . Sustainable Higher complexity spectral panels cannot be run on a conventional sorter Cytek sorter can also be used to sort panels from conventional analyzers CYTEK 15#161. Cytek' FSP Platform versus Other Technologies Conventional Flow Cytometry Biomarkers / Parameters (>40 biomarkers)¹ Sensitivity (nanoparticle detection) Throughput (>30K cell/second) Footprint (<150K cm³) Sorting Capability Cost Performance² CYTEK TRANSCEND THE CONVENTIONAL X X Spectral Flow Cytometry Xx X X X X Based on peer-reviewed publications Cost-to-Performance reflects performance based on accessible biomarkers, sensitivity, throughput and sorting capabilities, relative to costs associated with instruments, consumables, time, labor and ability to upgrade over time Mass Cytometry X X X X X CYTEK 16#17% NORMALIZED EMISSION Our FSP Technology Provides a Significant Reagents Opportunity Laser Violet Violet Violet Violet Violet Blue Blue Blue Blue Blue Blue Blue Blue Blue Blue Blue Yellow Green Red Red Red Red Red Red Violet Red Cytek developed a set of spectral unique dyes based on full spectrum cytometry About 20 cFluor dyes are identified and several have been commercialized Additionally, we market a cFluor immunoprofiling kit with 14 colors - Fluorescence spectrum of Cytek cFluor dyes can be stored in the instruments for ease of use and bundling with instruments 100 90- 80- 70- 80- 50- 40- 30- 20- 10- 04 U UV10 UV12 UN13 UNV14 UVIS LV16 EMISSION CHANNEL ROM YOU YO10 cFluor cFluor V420 cFluor V450 cFluor V500 cFluor V570 cFluor V620 cFluor B518 cFluor B532 cFluor B548 cFluor BYG575 cFluor BYG610 cFluor BYG628 cFluor BYG666 cFluor BYG676 cFluor BYG680 cFluor BYG710 cFluor BYG781 cFluor YG584 cFluor R659 cFluor R667 cFluor R685 cFluor R720 cFluor R780 cFluor R810 ViaViolet ViaRed CYTEK 17#18Reagents & Kits Portfolio CYTEK Reagents & Kits Commercially Launched October 2020 Our reagents are fluorochrome conjugated antibodies used to identify cells of interest Simplifies the workflow from sample preparation to data analysis Our 14-color cFluor immunoprofiling kit and 40-color optimized multicolor immunofluorescence panel provide users with ready-to-use protocols and antibodies Class 1 single-color reagents currently sold in China with clinical studies underway for 6-color TNBK reagents for potential Class 3 registration CYTEK | 18#19Web-Based Tool Developed to Help Customers to Advance HD Cell Analysis Fluorochrome Selection Guidelines CYTEK Cytek* Aurora Fluorochrome Selection Guidelines 5 Laser 16UV-16V-14B-10YG-8R Viclet Laser Excitable Dyes with Unique Signatures Spectrum Viewer Cytek Full Spectrum Viewer View and overlay full spectrum signatures Similarity and Complexity Indices Unmix Experiment At Contr MA OCC A *** Compare and evaluate fluorochrome combinations Experiment Builder ✓ SpectroFlo Experiment Builder Create SpectroFlo experiment templates s CYTEK 19#20End-to-End FSP Workflow 01 Animal or Human Samples Whole Blood PBMCs Tissue(s) Sample Collection 02 Tubes Sample Cell Plate Sample Preparation & Labeling 03 Aurora Spectral Signature SPECTROFLO DISPLAY Full Spectrum Profiling 04 Dot Plots Sample Acquisition Live Unmixing 05 Dimensionality Reduction Standardized, fully-integrated FSP workflow solution, incorporating instruments, reagents, software and services to provide a seamless end-to-end experience, increasing usage of high-dimensional cell analysis techniques by more end-users and accelerating market adoption Advanced Analysis CYTEK 20#21Development Strategy for Driving New Applications via Reagents Work with industry partners / KOLs to potentially co- develop new fluorophores and antibody conjugates with unique spectral characteristics Evaluate unique fluorophore prototypes to consider future development of additional products or processes + + Leukemia & Lymphoma Diagnosis Collaborations with Clinical Laboratories to design and study potential clinical diagnostics Identify and develop a larger range of conjugated antibodies that can be combined across each laser to increase the number of colors that can be effectively used together, with optimal resolution, in laboratory research and clinical diagnostics Minimal Residual Disease Monitoring CYTEK 21#22Comparable performance between 3-tube assays with CFC and 1-tube assays with NL-CLC New diagnosis method is discovered when multiple tubes are combined Legend: Live Single Cells Conventional 3-Tube Assay Full Spectrum NL-CLC 1-Tube Assay CD33 Myeloid Cells CD15 CD 13 Monocytes www. CD34 Mature Lymphocytes HLA-DR CD15 CD34+ Blast Cells CD117 CD38 CD34 CD33 CYTEK 22#23First 40-color Optimized Multicolor Immunofluorescence Panel LAC CYTOMETRY M OMIP-009: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood ISAC Donor 3444 Donor 3458 Donor 4559 Donor 5036 Number of colors/sotopes 50 40 30 20 10 0 First publication to go beyond 28-color fluorescence flow cytometry, exceeding OMIP panels published using mass cytometry 40-color panel covering almost the entire cellular composition of the human peripheral immune system with a single tube Higher throughput, robust population resolution and lower cost Mass cytometry Full spectrum flow cytometry K 6 1 PXE CYTEK = 2 5 5 10 12 8 1 6 11 5 5 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Publication year CYTEK 23#24Validation as Publications have Increased Significantly Over Time Cell 3 Q3 '18 Cancer Research 6 Q4 '18 AAGR 9 Q1 '19 JC inSIGHT 11 Q2 '19 The Journala Immunology 17 Q3 '19 24 Q4 '19 nature Advances INSIDE GREEN FLUORESCENT PROTEIN 44 Q1 '20 67 Q2 '20 103 Q3 '20 158 Q4 '20 211 Q1 '21 CYTEK | 24#25Growing Market Needs Require Advanced Cell Analysis 8 Flow cytometry used in clinical settings and provide new possibilities for novel drug development The Rise of Immuno-Oncology 8 Customers demand increased access to high parameter flow cytometry at both the high-end and low-end entry points Demands of Flow Cytometry Customers are Increasing DE Market is characterized by large, legacy players and a dearth of innovation, thus there is a large appetite for novel solutions Opportunity to Innovate a Market Suffering from Inertia The diagnostics sector has enjoyed a period of significant innovation, particularly within the fields of genomics and proteomics Clinical Diagnostics are Changing Drive adoption and application development of Cytek's FSP platform 25#26Cytek's Value Proposition to the Clinical Market M 22 NL-CLC M ■ Benefits ▪ Allows for more informative antibodies in one tube Minimizes use of redundant reagents Optimizes use of smaller amounts of patient specimen Identifies small populations of abnormal cells Improves overall laboratory efficiency Lowers costs . . Performs high-level multi-parameter flow cytometry immunophenotyping on small sample amounts ■ Accurately detects, diagnoses and monitors immune cell disorders with very low levels of key biomarkers Becoming a Solutions Provider for the Clinical Market Weite Automated Sample Preparation Customized Workflow Solutions Automated Analysis Error Reduction CYTEK 26#27The Power of "AND" Flow cytometry is often used with downstream or companion technologies Flow Cytometry Sorting Come Flow Cytometry Analysis Cytek cFluorTM Reagent Kits • Immuno-oncology • Immunotherapy • Infectious disease Minimal residual disease Next Gen Sequencing 10x illumina GENOMICS High Content Imaging Molecular Biology ADVANCED SCIENCE The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD L1 Open Acres ngu. Jus T Hai Kng Long uang. Yougong Ye Yongchang hang Gsorg Lel, Shuang Zhao; juan Su, Nong Vang Corg Peng xisowei xuSee at authors First 27 November 2020 http:/dol.org/10.1002/advs 202001586 ADVANCED www ADVANCED CINCE CYTEK 27#28Thought Leadership 1. Cytek is Transforming into a Full Solutions Provider 2 Establish Place instruments at top research universities and corporations across US, Europe and Asia 3. 000 750+ Instrument placements Drive Cutting- Edge Applications Focus on high value areas of scientific research and discovery 210+ Publications Position the Platform for Broad Use H™ Drive placements at pharma, biotech and CRO customers 125+ Biopharma Customers Translate into the Clinical Setting Develop applications for clinical setting using our FSP technology $23Bn Broader Cell Analysis TAM¹ 2024 market projection estimate We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adj. EBITDA Margin is on a percentage of revenue basis. For reference, 2020 Adjusted EBITDA was $14.9MM and 2020 Adjusted EBITDA margin was 16% Represents longer term financial objectives of the Company and does not constitute estimates of the Company's future performance, financial, or otherwise. There is no assurance that the Company will ever achieve any of these objectives. See Special Note Regarding Forward-Looking Statements Transformation into Solutions Provider End-to-end solutions provider, including instruments, reagents, software and services Strong and Scaling Adj. EBITDA2,3 CYTEK | 28#29Global Scale and Reach with Diversified Revenue Mix Since launch of Aurora Series in 2017... 620+ Customers 390+ Employees 125+ Biopharma Companies 25+ Countries WW Applications, Service & Sales % Revenue by Industry 51% 49% Fremont (Headquarters) Academic and Government-Owned Institutions ■Pharmaceutical and Biotechnology Companies, Distributors and CROS Bethesda Amsterdam % Revenue by Region USA 60% EMEA 28% APAC 12% Wuxi Shanghai Tokyo Other 1% CYTEK 29#301. Strong and Growing Base of Instrument Placements¹ 303 21 42 240 Q4'19A 376 21 62 293 Q1'20A 447 25 74 348 CAGR (Q4'19-Q1'21) 107% Q2'20A Aurora 548 28 96 424 Q3'20A Northern Lights Cumulative number of instruments (Aurora, Cell Sorter, Northern Lights and Athena) sold and delivered to our customers as of the dates presented 657 31 135 491 Q4'20A Athena 751 36 168 547 Q1'21A 851-856 Q2¹21E CYTEK | 30#31Historical Revenue and Gross Margin ($ in millions) Quarterly Revenue ($)1 / Gross Margin (%) $18.0 $1.9 47% $16.1 $19.1 $1.7 43% $17.4 $25.1 $1.9 Service Revenue 62% $23.2 $30.6 $2.0 Note: Fiscal year ended December 31 and first quarter ended March 31 1 Product revenue includes reagents 64% $28.6 $24.3 $1.6 60% $22.7 $30-$31 Q1'20A Q2¹20A Q3'20A Q4'20A Q1'21A Q2¹21E Product Revenue 64%-67% -Gross Margin Annual Revenue ($)1/ Gross Margin (%) $57.9 $7.7 50% $50.2 FY2019A Service Revenue YoY growth 60% Product Revenue $92.8 $7.6 56% $85.2 FY2020A -Gross Margin CYTEK | 31#32Historical Adjusted EBITDA ($ in millions) 2 YoY Quarterly Adj. EBITDA ($) / Adj. EBITDA Margin (%) 1,2 ($0.5) (3%) Q1'20A $1.8 7% Q1'21A Annual Adj. EBITDA ($) / Adj. EBITDA Margin (%) 1,2 $14.9 $3.3 6% FY2019A Note: Fiscal year ended December 31 and first quarter ended March 31 1. We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adjusted EBITDA Margin is on a percentage of revenue basis Reconciliation of Non-GAAP figures are in the appendix 16% FY2020A CYTEK 32#33Our Target Operating Model (as a % of revenue) Gross Margin % S&M % 2 R&D % G&A % Adj. EBITDA Margin %² Gross Margin ■ Shift in product mix with higher margin reagents becoming a greater share of total revenue ▪ Benefit from economies of scale as Company grows Leverage global manufacturing capabilities ■ FY2019A 50% 18% 15% 12% 6% S&M FY2020A Increased publications improve brand recognition and lowers customer acquisition costs 56% Improved variable costs to retain and service customers at scale 16% 15% 10% Key Improvement Drivers 16% Q1'21A 60% 18% 21% 16% 7% R&D ■ Lower cost to develop new products by leveraging existing FSP platform ■ Talent diversification in other lower cost locations ▪ Lower fixed costs to operate at scale Note: Fiscal year ended December 31 and first quarter ended March 31 1. Represents longer term financial objectives of the Company and does not constitute estimates of the Company's future performance, financial, or otherwise. There is no assurance that the Company will ever achieve any of these objectives. See special note regarding forward-looking statements. Reconciliation of Non-GAAP figures are in the appendix Long-Term Targets¹ G&A 65-70% -13% -13% -10% 30-35% • Improved operating costs through system automation ■ Talent diversification in other lower cost locations CYTEK | 33#34Advancing the Next Generation of Cell Analysis Tools High-Resolution, High-Content and High-Sensitivity Entire Spectrum of a Fluorescent Signal Integrated Platform Over 210 Peer-Reviewed Articles Global Scale and Reach Flexible, Easy-to-Use and Reconfigurable Lasers Differentiated, Cost-Effective and High Performance#35CYTEK TRANSCEND THE CONVENTIONAL Appendix#36Non-GAAP Adjusted EBITDA Reconciliation ($ in thousands) Net Income Adjustments Depreciation and amortization Provision for (benefits from) income taxes Interest Income Interest Expense Other (income) expense, net Litigation settlement Stock-based compensation Adjusted EBITDA Revenue Adjusted EBITDA Margin Note: Fiscal year ended December 31 and first quarter ended March 31 Q1'20A ($839) 105 178 (86) 37 105 ($500) $17,988 (3%) Q1'21A! FY19A FY20A $102 ($16,827) $19,411 167 50 (10) 375 615 456 $1,755 $24,272 7% 309 533 (711) 1 (252) 20,019 269 $3,341 $57,883 6% 603 (4,981) (110) 333 (994) 611 $14,873 $92,839 16% CYTEK 36 1